Table 1.
ACR Classification of GBCM Relative to Associations with NSF
| U.S. Trade Name | Generic Name | Structure | ACR Group |
|---|---|---|---|
| Omniscan | Gadodiamide | Linear nonionic | I |
| OptiMark | Gadoversetamide | Linear nonionic | I |
| Magnevist | Gadopentetate dimeglumine | Linear ionic | I |
| MultiHance | Gadobenate dimeglumine | Linear ionic | II |
| ProHance | Gadoteridol | Macrocyclic nonionic | II |
| Gadavist | Gadobutrol | Macrocyclic nonionic | II |
| Dotarem | Gadoterate meglumine | Macrocyclic ionic | II |
| Clariscan | Gadoterate meglumine | Macrocyclic ionic | II |
| Eovist | Gadoxetate disodium | Linear ionic | III |
Note: Group I: gadolinium-based contrast media (GBCM) associated with the greatest number of nephrogenic systemic fibrosis (NSF) cases. Group I GBCM are no longer advertised in the United States. Group II: GBCM associated with few, if any, unconfounded cases of NSF. Group III: GBCM for which data remains limited regarding NSF risk, but for which few, if any, unconfounded cases of NSF have been reported.
Abbreviation: ACR, American College of Radiology.